Pharmaceuticals Biotechnology and Life Sciences
More
-
June 18- The U.S. Food and Drug Administration on Tuesday said it was investigating the deaths of two patients who died following injections with Eli Lilly and Co's long-acting treatment for schizophrenia, called Zyprexa Relprevv.
-
DUBLIN, June 18- U.S.-based Royalty Pharma has dropped a hostile bid worth up to $8 billion for Elan, leaving the Irish drugmaker free to seek other suitors having put itself up for sale last week.
-
A Supreme Court decision gives the FTC the go-ahead to continue suing drug makers over deals that delay generic versions from being sold.
-
NEW YORK-- Shares of drug developer Synergy Pharmaceuticals Inc. traded higher Monday after a Citi Investment Research analyst started covering the stock with a "Buy" rating based on the company's constipation drug candidate plecanatide. THE BIG PICTURE: The New York company has no approved drugs, and plecanatide is its most advanced experimental product.
-
WASHINGTON, June 17- The U.S. Supreme Court ruled on Monday regulators can challenge deals between brand-name drug companies and generic rivals that delay cheaper medicines from going on sale, which regulators say increase costs to consumers by billions of dollars.
-
NEW YORK-- BioScrip Inc. plans to expand its drug infusion business with a $223 million acquisition of CarePoint, which administers drugs to patients in their homes and other locations outside of hospitals. BioScrip expects about $160 million in annual revenue from CarePoint, while BioScrip posted $663 million in revenue in 2012..
-
NEW YORK-- Teva Pharmaceutical Industries Ltd. said Monday that it is buying MicroDose Therapeutx for $40 million to build its pipeline of respiratory products. Teva, based in Israel, is one of the world's largest makers of generic drugs. U.S.-traded shares of Teva added 20 cents to $39.28 in Monday afternoon trading.
-
NEW YORK, June 17- ViroPharma Inc, a drug maker specializing in rare diseases, is attracting preliminary acquisition interest from several pharmaceutical companies, according to three people familiar with the matter.
-
NEW YORK, June 17- ViroPharma Inc is attracting preliminary interest from several pharmaceutical companies about buying the orphan drugmaker, according to three people familiar with the matter.
-
ALLEGAN, Mich.-- Perrigo Co. said Monday that it bought the ophthalmic ointment and solution portfolio of Fera Pharmaceuticals LLC for $93 million in cash. Perrigo has been looking for an ophthalmic deal as part of its strategy to expand its presence in the niche topical medication market.
-
The Supreme Court says deals between pharmaceutical companies and their generic drug competitors can sometimes be illegal.
-
WASHINGTON, June 17- The U.S. Supreme Court ruled on Monday that the Federal Trade Commission can challenge deals brand-name drug companies make with generic rivals that keep cheaper products off the market.
-
SOUTH SAN FRANCISCO, Calif.-- Drug developer Theravance Inc. plans to split into two independent, publicly traded companies after a royalty agreement it had ironed out with Irish drugmaker Elan Corp. PLC fell through. South San Francisco, Calif.- based Theravance said Monday it will split into businesses named Royalty Management Co. and Theravance Biopharma.
-
NEW YORK-- Shares of drug developer Synergy Pharmaceuticals Inc. rose Friday after its chairman disclosed that he'd bought more of the company's stock. THE SPARK: In a form filed with the Securities and Exchange Commission, Gabriele Cerrone disclosed the purchase of 8,000 shares for $4.42 per share.
-
DUBLIN/ NEW YORK, June 14- Irish drug company Elan put itself up for sale on Friday, seeking to fend off a hostile bid by Royalty Pharma that shareholders will consider next week. "Elan Corporation... today announced that it is proceeding with a formal sale process in light of the expressions of interest received to date," the company said in a statement.
-
Biotech drugmaker Amgen Inc. said Thursday that the Food and Drug Administration has approved a new use for its bone drug Xgeva. The company, based in Thousand Oaks, Calif., said it now can market Xgeva for treating a rare condition, giant cell tumor of bone, when surgery isn't practical.
-
A unanimous Supreme Court decision barred patents on naturally occurring DNA, but analysts said the ruling did little harm to biotech companies.
-
CNBC's Bertha Coombs reports shares of Myriad Genetics are hitting an all-time high after the Supreme Court ruled a naturally occurring human gene cannot be patented, but upheld key DNA patents of Myriad's BRACAnalysis test.
-
The Supreme Court ruled a naturally occurring human gene cannot be patented, but upheld key DNA patents of Myriad's BRACAnalysis test. CNBC's Bertha Coombs reports.
-
A check on biotech stocks after the Supreme Court justices say naturally occurring human genes cannot be patented, with CNBC's Seema Mody.
Most Popular Video
The Federal Reserve won't change course on quantitative easing this week, Steve Weiss of Short Hills Capital says.
Tuesday, 18 Jun 2013 | 7:10 AM ETAn airline passenger records a Chinese cargo handler as he tosses boxes of something on to and off of a conveyor belt for shipment. Hopefully, the cargo was packed well.
Tuesday, 18 Jun 2013 | 9:33 AM ETPlans to take PC maker Dell private by leveraging the company's balance sheet are misguided, CNBC's Jim Cramer said on "Squawk on the Street" Tuesday, because the company is facing lower margins and an increased competition from rival Hewlett Packard.